Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry D Altstiel

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology in Drug Development|April 2, 2019
Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc AnalysisAaron H Burstein, Scott J Brantley, Imogene Dunn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentLarry D Altstiel, Misty Lamendola, Wendy Luca, et al.
Current Alzheimer Research|May 8, 2014
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's diseaseElias M Schwam, Timothy Nicholas, Robert Chew, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 27, 2025
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's diseaseGarrett B Duncan, Samuel P Dickson, Johanne M Kaplan, et al.
Alzheimer Disease and Associated Disorders|June 19, 2002
Barriers to drug discovery and development for Alzheimer diseaseHoward M Fillit, Alan W O'Connell, William M Brown, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology in Drug Development|April 2, 2019
Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc AnalysisAaron H Burstein, Scott J Brantley, Imogene Dunn, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentLarry D Altstiel, Misty Lamendola, Wendy Luca, et al.
Current Alzheimer Research|May 8, 2014
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's diseaseElias M Schwam, Timothy Nicholas, Robert Chew, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 27, 2025
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's diseaseGarrett B Duncan, Samuel P Dickson, Johanne M Kaplan, et al.
Alzheimer Disease and Associated Disorders|June 19, 2002
Barriers to drug discovery and development for Alzheimer diseaseHoward M Fillit, Alan W O'Connell, William M Brown, et al.
Pageof 1